NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the…
Pharmacologic Class:
Prostaglandin Analog
Loss of Exclusivity
LOE Date
Jul 8, 2031
65 months away
Patent Expiry
Jul 8, 2031
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8637054 | Jul 8, 2031 | Product | U-446 |
Company
Thea Pharma
MA - Waltham